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Abstract
Protein synthesis inhibitors are commonly used for measuring protein degrada-
tion rates, but may cause cytotoxicity via direct or indirect mechanisms. This
study aimed to identify concentrations providing optimal inhibition in the
absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine, and pur-
omycin were assessed individually, and in two-, three-, and four-drug combina-
tions for protein synthesis inhibition (IC50) and cytotoxicity (CC50) over 72 h.
Experiments were conducted in HepG2 cells and primary rat hepatocytes
(PRH). IC50 for actinomycin D, cycloheximide, emetine, and puromycin were
39  7.4, 6600  2500, 2200  1400, and 1600  1200 nmol/L; with corre-
sponding CC50 values of 6.2  7.3, 570  510, 81  9, and 1300  64 nmol/L,
respectively, in HepG2 cells. The IC50 were 1.7  1.8, 290  90, 620  920, and
2000  2000 nmol/L, with corresponding CC50 values of 0.98  1.8,
680  1300, 180  700, and 1600  1000 (SD) nmol/L, respectively, in PRH.
CC50 were also lower than the IC50 for all drug combinations in HepG2 cells.
These data indicate that using pharmacological interference is inappropriate for
measuring protein degradation over a protracted period, because inhibitory
effects cannot be extricated from cytotoxicity.
Abbreviations
CC10, cytoxicity concentration at 10% of maximum (90% cell viability); CC50,
cytoxicity concentration at 50% of maximum (50% cell viability); DDIs, drug–drug
interactions; FICs, fractional inhibitory concentrations; GST, glutathione S-transfer-
ase; HBSS, Hank’s balanced salt solution; HepG2, hepatocellular carcinoma cell line;
kdeg, degradation rate constant; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide; PBPK, physiologically based pharmacokinetic; PRH, primary
rat hepatocyte.
Introduction
Protein abundance in a cellular system is a balance
between the rate of synthesis and degradation. The ability
of the cell to remove and replenish proteins in a dynamic
state of constant turnover is paramount to maintaining
essential cellular functions. While rates of protein synthe-
sis are readily measurable by time-course experiments
utilising radioisotopes and protein quantification, the rate
of degradation (kdeg) is often more difficult to determine
especially in vivo (Millward et al. 1981; Pratt et al. 2002).
This is due to the complex interplay between different pro-
tein degradation mechanisms and paucity in understanding
the causal signalling mechanisms initiating specific protein
degradation. Protein degradation is commonly quantified as
half-life, the time taken for protein to decrease by half (Zhou
2004; Belle et al. 2006; Zhang et al. 2007). This variable is
interchangeable with kdeg by the following equations
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assuming first-order decay kinetics (Belle et al. 2006), where
N is the protein intensity, k is the decay rate constant (and –
k represents kdeg), and t1/2 is the half-life:
N ¼ N0ekt (1)
ln Nð Þ  ln N0ð Þ ¼ kt ) t1
2
¼ ln 2ð Þ
k
(2)
k ¼ ln N½   ln N0½ ð Þ  t (3)
Physiologically based pharmacokinetic (PBPK) mod-
elling can be used to predict the magnitude and dynamics
of drug–drug interactions (DDIs), allowing the investiga-
tion of optimal timings for washout periods or switching
of drug regimens in clinical practice. Such approaches
require robust drug and system parameters (Jamei et al.
2009; Rostami-Hodjegan 2012). Clearly, kdeg is a critical
system parameter for the simulation of time-dependent
DDIs, such as those mediated by mechanism-based inhi-
bition or induction (Venkatakrishnan and Obach 2007;
Almond et al. 2009).
Several sources have highlighted the lack of accurate
kdeg data for metabolising enzymes and transporter pro-
teins as important sources of error in DDI prediction
(Obach et al. 2007; Wang 2010). Despite its well-estab-
lished impact, there is large disparity in the literature for
the kdeg of specific proteins and different values are used
for the same enzyme across different studies, resulting in
inconsistent predictions (Ghanbari et al. 2006; Yang
et al. 2008; Wang 2010; Yeo et al. 2011). Proteins have
widely varied half-lives, ranging from minutes to several
days, and protein turnover is tightly regulated through
multiple molecular mechanisms. Apart from the impor-
tance in PBPK, further characterisation of kdeg for speci-
fic proteins is required for better understanding of cell
signalling processes involved in both normal and dys-
functional diseased cell states, thus studies of protein
turnover are used in many different areas of cellular and
molecular biology.
Traditional methods of protein degradation measure-
ment and derivation of kdeg, fall into two experimental
designs: (1) quantifying the amount of a specific protein
before and after a cell perturbation then measuring the
difference in protein abundance and time between the
initial and new steady-state; or (2) quantifying changes in
protein abundance by kinetic, time-course experiments
(Alvarez-Castelao et al. 2012). The kinetic approach is
based on an initial cell treatment with protein synthesis
inhibitors followed by the quantification of changes in
protein content over time by immunoblotting (Dai et al.
2013). Traditional methods of measuring protein degra-
dation generally utilise low level incorporation of radiola-
belled amino acids in the form of pulse-chase analysis,
often involving the use of protein synthesis inhibitors to
eliminate reincorporation (Zhou 2004; Doherty et al.
2009). The more recent approaches focus on simultane-
ously measuring the rates of a large number of proteins.
For example, stable isotope labelling by amino acids
(SILAC) in cell culture followed by mass-spectrometry
(MS) as a common proteomics-based method for mea-
suring protein turnover rates (Mann 2006; Doherty et al.
2009; Fierro-Monti et al. 2013; Takahashi et al. 2017) and
isobaric tag for relative and absolute quantification
(iTRAQ) are also used (Jayapal et al. 2010). The focus of
this study was on the more traditional methods of mea-
suring protein degradation utilising protein synthesis
inhibitors for pharmacological interference.
The aim of this study was to find a suitable protein
synthesis inhibitor or drug combination that provided
maximum protein synthesis inhibition with minimum
cytotoxicity for subsequent use in measuring protein
degradation rates. The four selected inhibitors actino-
mycin D, cycloheximide, emetine, and puromycin were
assessed alone and in combination to determine their
suitability for protein degradation studies. Leucine incor-
poration assays and standard 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays were
employed to determine the level of protein synthesis inhi-
bition and cytotoxicity, respectively, across a range of
drug concentrations in immortalised hepatic cell line and
primary hepatocytes. Two-drug combinations were tested
for synergy by the modified fixed-ratio isobologram
method. Combinations of three and four inhibitors were
assessed at subcytotoxic concentrations of each inhibitor.
Materials and Methods
Materials
Dulbecco’s modified eagle medium (DMEM), fetal bovine
serum (FBS), trypsin-EDTA solution, Hank’s balanced salt
solution (HBSS), thiazolyl blue tetrazolium (TBT), and
protein synthesis inhibitors (actinomycin D (A4262),
emetine dihydrochloride hydrate (E2375), and puromycin
dihydrochloride (P7255)) were purchased from Sigma-
Aldrich (Dorset, UK). HepG2 cells were purchased from
American Tissue Culture Collections (ATCC, Virginia).
Cryopreserved primary rat hepatocytes, William’s E
media, plating cocktail, maintenance cocktail, Geltrex
matrix, and collagen I coated plates were purchased from
Invitrogen Ltd (Paisley, UK). Cycloheximide (ab120093)
was purchased from Abcam (Cambridge, UK). L-Leucine
[4,5-3H] (MT-672E) was obtained from Moravek (Cali-
fornia). The CellTiter-Glo cell viability assay and the
GSH-Glo glutathione assay were purchased from Promega
(Southampton, UK).
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Cell line culture
HepG2 cells were grown in DMEM medium supple-
mented with 10% FBS solution and were discarded
beyond passage 20. The media was changed every 48 h
and cells were cultured until 80–90% confluence in a
37°C 5% CO2 humidified incubator. Cell counts were
carried out by a Nucleocounter (Chemometec, Denmark).
Primary rat hepatocyte culture
Primary rat hepatocytes (PRH) were purchased from
Invitrogen (Paisley, UK), isolated from male Sprague–
Dawley rats at 9 weeks old (Lot. RS745). Cryopreserved
PRH were thawed in a 37°C water bath for approximately
2 min until contents were around 90% thawed. Once
thawed, the hepatocytes were added to 50 mL of pre-
warmed plating media (William’s E media without phenol
red supplemented with 5% FBS, 1 lmol/L dexametha-
sone, 1% solution of penicillin/streptomycin, 4 lg/mL
bovine insulin, 2 mmol/L GlutaMAXTM, and 15 mmol/L
HEPES (CHRM supplement A), and centrifuged for
3 min at 55g at 18°C and the supernatant fraction dis-
carded. The hepatocytes were then resuspended in plating
media at 1 9 106 cells per ml density.
The cell viability of primary human hepatocytes was
calculated using the Chemometec NucleoCounter NC-
100TM according to the manufacturer’s protocol. Cells
were seeded in collagen coated plates and were incubated
for 5 h at 37°C with 5% CO2 and 95% humidity. After
5 h incubation, plating media was discarded and replaced
with 0.022 mg/mL of Geltrex Matrix in maintenance
media (William’s E media supplemented with 0.1 lmol/
Ldexamethasone, 0.5% penicillin/streptomycin 6.25 lg/mL
human recombinant insulin, 6.25 lg/mL human transfer-
rin, 6.25 ng/mL selenous acid, 1.25 mg/mL BSA, 5.35 lg/
mL linoleic acid, 2 nmol/L GlutaMAXTM, and 15 mM
HEPES). After incubation overnight, media containing Gel-
trex was removed and replaced with varying drug con-
centrations and controls in maintenance media.
Measuring protein synthesis inhibition by
[3H]-leucine incorporation
HepG2 cells were seeded at 2 9 105 cells per well in
DMEM supplemented with 10% FBS and the plates were
incubated overnight at 37°C to allow cells to adhere. PRH
cells were seeded in collagen coated 24-well plates at a
density of 2 9 105 cells per well. Old media was removed
and replaced with 0–100 lmol/L of protein synthesis
inhibitors dissolved in DMEM with 10% FBS for HepG2
cells or maintenance media for PRH and incubated for
72 h in a 37°C humidified incubator. In the last 2 h of
incubation, cells were pulsed with 2 lCi of [3H]-leucine
without removing the inhibitor. After 2 h, the media con-
taining [3H]-leucine was removed by aspiration and the
cells were washed with HBSS before removal from well by
trypsinisation. HepG2 cells were then harvested onto a fil-
termat using a TomTec cell harvester. The filtermat was
sealed in a sample bag with melt-on scint and the level of
protein synthesis was determined by the level of [3H]-leu-
cine incorporation measured using a MicroBeta detector
(Perkin-Elmer, Cambridge, UK). PRH cells were trans-
ferred to scintillation vials and radioactivity was deter-
mined using QuantaSmartTM software on a Tri-Carb
scintillation counter (Perkin-Elmer).
Measuring cell viability by standard MTT
Assays
Standard MTT assays were performed on HepG2 and
PRH cells to measure cell viability. 2 9 104 cells per well
of HepG2 were seeded into 96-well plates in DMEM with
10% FBS and left overnight in a 37°C humidified incuba-
tor to allow cells to adhere to the plate. PRH were seeded
in collagen coated 96-well plates at a density of 2 9 104
cells per well. Old media was removed and replaced with
0–300 lmol/L of protein synthesis inhibitors and incu-
bated for 72 h. A vehicle control and control with no
drug was included. A quantity of 20 lL of 5 mg/mL TBT
in HBSS was added to each well and incubated for 2 h. A
quantity of 100 lL lysis buffer (50% v/v dimethyl-
formahyde and 20% v/v sodium dodecyl sulphate) was
added to each well and the plate was incubated overnight
at 37°C. The absorbance was quantified at 570 nm by a
Tecan GENios micoplate reader (Germany).
Single protein synthesis inhibitor analysis
The protein synthesis inhibitors actinomycin D, cyclohex-
imide, emetine, and puromycin were analysed individually
in HepG2 and PRH cells. Actinomycin D was incubated
0–10 lmol/L and 0–0.039 lmol/L and puromycin at 0–
20 lmol/L and 0–5 lmol/L for leucine incorporation
assays and MTT cytotoxicity assays, respectively. Cyclo-
heximide was incubated at 0–300 lmol/L and emetine at
0–30 lmol/L for both leucine incorporation and MTT
assays.
Two-drug combination fixed-ratio
isobologram analysis
The effects of two-drug combinations on HepG2 cells
were assessed by the modified fixed-ratio isobologram
protocol, which detects synergy, additivity, or antagonism
between a pair of drugs (Fivelman et al. 2004). Stock
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solutions of the drugs were prepared at 10 mmol/L in
sterile distilled water. Concentration–response assays
were carried out to obtain the IC50 and CC50 of the
individual drugs by leucine incorporation and standard
MTT assays, respectively. For the six two-drug combina-
tions, the drug dilutions were made to allow the IC50 or
CC50 to fall at about the fourth threefold serial dilution.
The dilutions of each of the two drugs in each combina-
tion were prepared in seven fixed ratios 6:0, 5:1, 4:2, 3:3,
2:4, 1:5, and 0:6. These mixtures were then serially
diluted threefold in quadruplicates to generate a range of
eight concentrations for each condition. Protein synthesis
inhibition and cell viability assays were conducted as
described above to generate a concentration–response
curve to calculate the IC50 and CC50 for drugs A and B
in each mixture. The fractional inhibitory concentrations
(FICs) were calculated using Equation 4,5, and 6 (Gorka
et al. 2013):
FICA ¼ IC50 or CC50 of drug A in combination
IC50 or CC50 of drug A alone
(4)
FICB ¼ IC50 or CC50 of drug B in combination
IC50 or CC50 of drug B alone
(5)
FICindex ¼ FICA þ FICB (6)
Isobologram curves were generated by plotting FICA
versus FICB. FICindex = 1 was taken as indicative of an
additive effect between drugs A and B, FICindex<1 indica-
tive of synergy and FICindex>1 indicative of antagonism.
Three- and four-drug combination analysis
Three-drug combinations: actinomycin D, cycloheximide,
and emetine; actinomycin D, puromycin, and emetine;
actinomycin D, puromycin, and cycloheximide; and puro-
mycin, cycloheximide and emetine, and four-drug combi-
nation: actinomycin D, puromycin, cycloheximide, and
emetine were assessed at subcytotoxic concentrations of
each drug (determined from the single drug incubation
experiments) in HepG2 cells. The three- and four-drug
combinations were made up at the CC10 concentrations
and measured for level of protein synthesis inhibition by
[3H]-leucine incorporation and assessed for cytotoxicity
by several different toxicity assays.
Standard MTT assay
Standard MTT assays were performed on the three-
and four-drug combinations using methods described
above in HepG2 cells. Further toxicity assays (CellTiter-
Glo, GSH-GloTM glutathione, and trypan blue exclu-
sion) were performed on these combinations to confirm
the robustness of MTT assays as a measure of cell via-
bility.
CellTiter-Glo luminescent cell viability assay
A CellTiter-Glo luminescent cell viability assay was per-
formed on the above drug combinations following 72 h
incubation in HepG2 as described in the manufacturer’s
protocol. Cells were seeded at 2 9 104 cells per well in
DMEM with 10% FBS. The assay measures the amount
of ATP present that indicates the presence of metaboli-
cally active viable cells.
GSH-GloTM glutathione assay
GSH-GloTM glutathione assays were performed on the
above drug combinations following 72 h incubation in
HepG2 cells according to the manufacturer’s protocol.
Cells were seeded at 1 9 104 cells per well in DMEM
with 10% FBS. The assay measures the conversion of a
luciferin derivative into luciferin in the presence of glu-
tathione and glutathione S-transferase (GST) as an indica-
tion of oxidative stress.
Trypan blue exclusion
HepG2 cells were seeded at 5 9 104 cells per well in
DMEM +10% FBS and incubated with the three- and
four-drug combinations for 72 h. Following incubation,
the cells were washed with HBSS solution and trypsinised
for 5 min before being transferred in suspension to
Eppendorf tubes. A quantity of 10 lL of cell suspension
was added to 10 lL of trypan blue solution and placed
on a CountessTM slide. Cell viability was calculated using a
CountessTM automated cell counter (LifeTechnologies,
UK).
Data analysis
The IC50 (concentration causing 50% protein synthesis
inhibition), CC50 (concentration causing 50% cell viabil-
ity), and CC10 (concentration causing 90% cell viability)
were calculated by nonlinear regression of drug concen-
tration versus leucine incorporation and MTT concen-
tration–response graphs, respectively, using Graphpad
Prism 3 software. The IC50 and CC50 values derived
from the single inhibitor analyses were used for subse-
quent fixed-ratio isobologram two-drug combination
analyses.
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Results
Single protein synthesis inhibitor
The mean  SD CC50 for the four protein synthesis inhi-
bitors actinomycin D, cycloheximide, emetine, and puro-
mycin were found at 6.2  7.3, 570  510, 81  9, and
1300  64 nmol/L, respectively, in HepG2 cells and
0.98  1.8, 680  1300, 180  700, and 1600 
1000 nmol/L, respectively, in PRH. The IC50 were
39  7.4, 6600  2500, 2200  1400, and 1600 
1200 lmol/L, respectively, in HepG2 and 1.7  1.8,
290  90, 620  920, and 2000  2000 nmol/L, respec-
tively, in primary rat hepatocytes. The IC50 and CC50
concentrations were calculated from concentration–re-
sponse graphs as shown in Figure 1. The CC50 concentra-
tions were lower compared to corresponding IC50 values
for all four inhibitor drugs except cycloheximide in PRH;
this indicates that the inhibitors were more effective in
generating cell death than protein synthesis inhibition
and thus unsuitable for further protein degradation stud-
ies.
Figure 2 shows linear regression between the IC50 and
CC50 values derived from HepG2 and cryopreserved PRH
cells. Figures 2A–C show linear relationships between the
IC50 and CC50 between HepG2 and PRH cells for actino-
mycin D, emetine, and puromycin. Cycloheximide fit in
the linear relationship for cytotoxicity but not for protein
synthesis inhibition.
Two-drug protein synthesis inhibitor
combinations
The fixed-ratio isobologram method was employed to
assess additivity, synergy, or antagonism in both protein
synthesis inhibition and cytotoxicity between drug pairs.
Six combinations of drug pairs for the four inhibitors
were analysed. The combinations cycloheximide and eme-
tine, cycloheximide and puromycin, and emetine and
puromycin showed antagonism for protein synthesis inhi-
bition at all ratios (as shown in Fig. 3A–C) and were
therefore deemed to be unsuitable for protein degradation
studies. As such, isobolograms to assess cytotoxicity were
not carried out for these combinations. Actinomycin D
and emetine showed additivity (no interaction) between
the drugs for protein synthesis inhibition and synergy for
cytotoxicity, indicating that actinomycin D and emetine
did not increase protein synthesis inhibition in combina-
tion but did display higher cytoxicity. As such, this com-
bination was also deemed unsuitable for measuring
protein degradation rates. Actinomycin D and cyclohex-
imide, and actinomycin D and puromycin did show syn-
ergy for protein synthesis inhibition at some ratios. This
combination also displayed strong synergy for cytotoxicity
at most ratios. Interestingly, at ratios of 5:1 and 4:2 for
actinomycin D: cycloheximide and actinomycin D: puro-
mycin, these combinations were synergistic for protein
synthesis inhibition and antagonistic for cytotoxicity as
seen in Figure 3D and F, respectively. However, despite
the synergy for protein synthesis inhibition and antago-
nism for cytotoxicity at these ratios, the CC50 values for
these drug pairs alone and in combination were still lower
than the IC50 values and thus cytotoxicity was observed at
lower concentrations than those required to inhibit pro-
tein synthesis. The CC50 concentrations for actinomycin
D in combination with cycloheximide at 5:1 and 4:2
ratios were 12 and 14 nmol/L and the corresponding
IC50 concentrations were 28 and 35 nmol/L, respectively.
The CC50 values for cycloheximide in combination with
actinomycin D at 5:1 and 4:2 ratios were 26 and
12 nmol/L and the corresponding IC50 concentrations
were 2500 and 1300 nmol/L respectively. For the combi-
nation actinomycin D and puromycin, the CC50 concen-
trations for actinomycin D at 5:1 and 4:2 ratios were 9.8
and 8.1 nmol/L and the corresponding IC50 concentra-
tions were 16 and 21 nmol/L respectively. As for puromy-
cin, the CC50 values at 5:1 and 4:2 ratios were 60 and
20 nmol/L and the corresponding IC50 concentrations
were 690 and 360 nmol/L respectively.
Three- and four-drug combination analysis
The four inhibitors individually and the two-drug combi-
nations displayed high cell death. Three- and four-drug
combinations at subtoxic concentrations (CC10 of each
when incubated alone) were, therefore, assessed to investi-
gate whether protein synthesis inhibition could be
achieved at concentrations lower or equal to those caus-
ing cytotoxicity. The CC10 (90% cell viability concentra-
tion) were calculated for each drug to be 0.17, 24, 7.0,
and 110 nmol/L for actinomycin D, cycloheximide, eme-
tine, and puromycin, respectively, in HepG2 cells. As
mentioned previously, the inhibitors alone displayed a
lower concentration for CC50 than IC50 indicating that
they were more effective in generating cell death than
inhibiting protein synthesis. The four-drug combination
showed a high 76% protein synthesis incorporation (thus
low inhibition) and high cytotoxicity across all cytotoxic-
ity assays as seen in Figures 4 and 5. Three-drug combi-
nations: actinomycin D, cycloheximide, and emetine;
actinomycin D, cycloheximide, and puromycin; and acti-
nomycin D, puromycin and emetine also demonstrated
low protein synthesis inhibition with high cytotoxicity,
also seen in Figures 4 and 5. Although puromycin, cyclo-
heximide, and emetine gave low cell death across the
assays, it was also ineffective at inhibiting protein
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synthesis inhibition, as shown in Figure 4, where level of
leucine incorporation is higher than control. Overall,
three- and four-drug combinations of these protein syn-
thesis inhibitors were deemed to be unsuitable for further
protein degradation studies even at low concentrations.
Discussion
The use of protein synthesis inhibitors is the most com-
mon method for measuring protein degradation rates and
has been documented by many sources over four decades
(Goldberg and Dice 1974; Curfman et al. 1980; Princiotta
et al. 2003; Zhou 2004; Belle et al. 2006; Delgado-Vega
et al. 2012; Chistyakov et al. 2014). The more recent
approaches focus on simultaneously measuring the rates
of a large number of proteins. For example, (SILAC) in
cell culture followed by (MS) as a common proteomics-
based method for measuring protein turnover rates
(Mann 2006; Doherty et al. 2009; Fierro-Monti et al.
2013; Takahashi et al. 2017) and (iTRAQ) are also used
(Jayapal et al. 2010). However, the wide application of
these proteonomic approaches are limited by cost and
complexity. The focus of this study was on the more sim-
ple traditional methods of measuring protein degradation
utilising protein synthesis inhibitors for pharmacological
interference. The aim of this study was to define inhibitor
concentrations (single or combinations) that provide
maximum protein synthesis inhibition with minimum
cytotoxicity that could then be used in subsequent experi-
ments to accurately estimate endogenous degradation
rates.
For this study, four protein synthesis inhibitors actino-
mycin D, cycloheximide, emetine, and puromycin were
selected based on their different mechanisms of action
and previous use in biomedical research. Actinomycin D
(Sobell 1985) intercalates DNA forming a stable complex
with deoxyguanosine residues, thus blocking movement
of RNA polymerase and subsequently transcription.
Cycloheximide binds the 60S ribosomal subunit blocking
the translocational step in amino acid elongation, thus
inhibiting protein synthesis (Schneider-Poetsch et al.
2010). Emetine inhibits protein synthesis by binding onto
the 40S subunit of ribosomes and inhibiting translocation
of proteins (Akinboye and Bakare 2011). Puromycin acts
as an analogue of the 30-terminal end of aminoacyl-tRNA,
which results in premature amino acid chain termination
Figure 2. Linear regression analysis of IC50 and CC50 between
HepG2 and PRH cell types. (A) shows linear regression between CC50
values of the four protein synthesis inhibitor drugs for the different
cell types. (B) shows linear regression between IC50 values with
cycloheximide omitted but shown in inset graph, of the two cell
types. (C) shows IC50:CC50 ratio of HepG2 and PRH cell
types omitting cycloheximide. Cycloheximide is included in the inset
graph.
Figure 1. IC50 and CC50 of the four individual protein synthesis inhibitors in HepG2 and primary rat hepatocytes (PRH). (A–D) Cell viability was
measured by standard MTT assay and expressed as viability as a percentage of untreated control. (E–H) Protein synthesis inhibition across different
concentrations of inhibitors was measured by [3H]-Leucine incorporation assay and shown as percentage of inhibition of control. Dotted line
shows PRH and solid line for HepG2 cells. Dose–response curves were produced by Prism software and IC50 and CC50 values were calculated
from linear regression models. Data are shown as mean  SD from n = 3 independent experiments.
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during translation of proteins (Azzam and Algranati
1973).
This study supports reported concerns over the inhi-
bitors being too disruptive to normal cellular function
to use to measure natural rates of protein turnover
(Yewdell et al. 2011; Geva-Zatorsky et al. 2012). In all
cases, the CC50 concentration for the drugs in combina-
tion was lower than the corresponding IC50, suggesting
that even in combination protein synthesis inhibition
could not be studied in the absence of an effect on
other cellular functions. These data suggest that inhibit-
ing mechanisms of protein synthesis by pharmacological
interference (even with lower concentration combina-
tions) is not a physiologically appropriate method of
measuring kdeg because all protein systems, including
those involved in protein degradation pathways, are
likely to be affected. In support of this, Dai et al.
reported that cycloheximide could affect protein degra-
dation by activating the AKT (protein kinase B) leading
to downstream effects on the normal functioning of the
ubiquitin proteasome degradation (UPD) pathway (Dai
et al. 2013). In addition to the drugs disrupting protein
degradation machinery, there have been reports of pro-
tein synthesis inhibitors actively inducing a range of
protein mRNA production that also impact accuracies
for calculating protein degradation rates downstream
(Hattori and Gross 1995; Schuetz et al. 1995; Stordeur
et al. 1995). It should be noted that the incubation
Figure 3. Isobolograms generated based on CC50 and IC50 values showing the interaction between protein synthesis inhibitor pairs. Six
combinations of inhibitor pairs are shown in (A–F) The dotted line corresponds to the predicted curve if drug pairs showed an additive effect. The
black line corresponds to drug pair interactions for protein synthesis inhibition. The grey line shows drug pair interactions for cytotoxicity. FICA
and FICB correspond to the fractional inhibitory concentrations of the first and second drugs in each drug pair listed. Cytotoxicity analysis was not
performed for cycloheximide–emetine, cycloheximide–puromycin, and emetine–puromycin drug pairs (A–C) as these showed strong antagonism
for protein synthesis inhibition. N = 4 independent experiments were carried out in HepG2 cells.
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time with the protein synthesis inhibitor drugs was for
72 h in the current study and as such, measurement of
degradation for proteins with medium or long (over
72 h) half-lives are likely to be particularly problematic.
Further optimisations with shorter incubation periods
may be possible for proteins with shorter t1/2 but
robust optimisation will be required.
Protein synthesis inhibitors are commonly used for
measuring protein degradation yet in previous studies,
there has been little consideration for their cytotoxic
effects and virtually none have optimised a specific con-
centration to use. Several studies have used cycloheximide
at millimolar concentrations, which was much higher
than the nontoxic concentration range found here (Pan
Figure 4. The level of [3H]Leucine incorporation for three- and four-inhibitor combinations at subcytotoxic concentrations (CC10). Leucine
incorporation assays were carried out in HepG2 cells and the percentage of incorporation compared to control was calculated. Combination APCE
corresponds to actinomycin D, puromycin, cycloheximide, and emetine; ACE to actinomycin D, cycloheximide, and emetine; APE to actinomycin
D, puromycin, and emetine; APC to actinomycin D, puromycin, and cycloheximide; and PCE to puromycin, cycloheximide, and emetine. Data are
shown as mean  S.D from n = 3 independent experiments.
Figure 5. Measuring cytotoxicity for the three- and four-inhibitor combinations at subcytotoxic concentrations. Three- and four-inhibitor
combinations were prepared at CC10 concentrations. A range of cytotoxicity assays including standard MTT, GSH, ATP, and trypan blue exclusion
assays were conducted on HepG2 cells. APCE corresponds to actinomycin D, puromycin, cycloheximide, and emetine; ACE to actinomycin D,
cycloheximide, and emetine; APE to actinomycin D, puromycin, and emetine; APC to actinomycin D, puromycin, and cycloheximide; and PCE to
puromycin, cycloheximide; and emetine. Data are shown as mean  SD from n = 3 independent experiments.
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and Haines 1999; Princiotta et al. 2003; Jeong et al. 2005;
Xie et al. 2010; Majumder et al. 2012). MTT assays were
used as the main method of measuring CC50 and the level
of cytotoxicity across the four protein synthesis inhibitor
drugs and their combinations. Since MTT assays specifi-
cally assess the formazan production pathway as a mea-
sure of cellular mitochondrial damage, other forms of
cytotoxicity assays including GSH, ATP, and trypan blue
exclusion, which assess other mechanisms of cytotoxicity,
were carried out to validate the findings. Good agreement
across assays and drug combinations was observed with
the exception of puromycin, cycloheximide, and emetine
in which higher cellular toxicity was detected in MTT
than other assays. Despite GSH assays showing higher cell
viability across the different drug combinations, it should
be noted that GSH assays alone could not be used to pre-
dict the CC50 in this study because the results were in dis-
agreement with the other cytotoxicity assays employed. A
potential limitation is that protein binding was not
assessed in this study. However, it should be recognised
that protein binding would be expected to impact both
cytotoxicity and protein synthesis inhibition by impacting
free-drug concentration. Thus, the ratio would not be
expected to be different.
Earlier studies with actinomycin D and puromycin
reported toxicity in HeLa cells at concentrations within
the range investigated here. Studies by Sawicki and
Godman (1971) showed that at 0.08 lmol/L actino-
mycin D was sufficient to cause cell toxicity in HeLa
cells, which is in agreement with the present findings.
Dudani et al. (1988) proposed that puromycin caused
cytotoxicity at 0.9 lmol/L in human cell lines, including
HeLa cells, which also agreed with the presented results.
Dudani et al. also reported a 79.6% protein synthesis
inhibition at 0.9 mmol/L in HeLa cells which further
supports our findings that puromycin is cytotoxic at
concentrations lower than those required for protein
synthesis inhibition. Conversely, Yin Low et al. (2009)
conducted cytotoxicity assays on emetine in Huh-7 cells
and reported over 90% cell viability at 10 lmol/L
which is much higher concentrations than those used
here. Although the reason for this disparity is not
apparent, cytotoxicity of these inhibitors may vary
between different cell types. The single drug analyses
were carried out in HepG2 and primary rat hepatocytes
with reasonable agreement in protein synthesis inhibi-
tion and cytotoxicity for actinomycin D, emetine, and
puromycin as shown in the linear relationship displayed
in Figure 2. This study was carried out in readily avail-
able HepG2 cells and primary rat hepatocytes with the
aim of transferring the optimised conditions onto pri-
mary human hepatocytes to validate a more physiologi-
cally accurate kdeg prediction (Wilkening et al. 2003).
However, due to the presented findings, an alternative
approach to kdeg determination is now being explored.
Despite the wide-ranging importance of protein degra-
dation, there has been no single recognised method for its
measurement. However, these data indicate that the use
of protein synthesis inhibitors should be avoided. The
more recent methods of measuring rates of degradation
focus on high-throughput approaches aiming to quantify
many different proteins in parallel; these involve meta-
bolic labelling of proteins of interest followed by MS anal-
ysis (Doherty and Beynon 2006). Newly developed
quantitative proteonomic methods provide an important
alternative to chemical inhibition, however, reproducibil-
ity across different experiments and the impact of protein
labelling on endogenous protein degradation warrants full
investigation.
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